What is the role of suramin in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print


Suramin acts via growth factor inhibition and remains active in patients with hormone-refractory cancer. This drug may be used in combination with other agents. Adverse effects include the following:

  • Edema
  • Leukopenia
  • Infection
  • Hyperglycemia
  • Anemia
  • Anorexia
  • Dyspnea
  • Platelet abnormalities
  • Elevated creatinine levels
  • Malaise
  • Arrhythmias
  • Coagulopathy

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!